Eight threads — three on commercial growth, four on pipeline, one on regulatory headwind.
↓ scroll to read
✦ The bottom line
Iovance's Q1 release is a commercial update with clinical data attached. Here's how management framed the quarter.
↓ the brief below
✦ Eight threads from the Q1 2026 earnings release
1
Amtagvi revenue grew 45%.
$60M of US Amtagvi revenue plus $11M of global Proleukin — total $71M, a 45% YoY gain despite Q1's planned facility maintenance.
2
Manufacturing was the gating variable.
The iCTC facility was offline for annual maintenance in Q1. Iovance has expanded the facility to ensure continuous supply through future maintenance windows.
3
Gross margin hit 41%.
Even absorbing one-time maintenance and expansion costs, 41% gross margin is a strong number for cell therapy — and should expand as utilization rises.
4
Q2 and FY guidance was raised.
$86-88M in Q2, $350-370M full year — implies ~35% YoY growth for 2026 versus 2025's $263M.
5
Endometrial cancer data hit 40% cORR.
IOV-END-201 reported 40% confirmed objective response rate and 100% disease control rate in serous endometrial cancer — a difficult tumor type with no approved targeted therapy.
6
Sarcoma trial is now registrational.
IOV-SAR-201 trial started in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma — both registrational, both built on a 50% cORR in early data.
7
The next-generation pipeline filed an IND.
IOV-5001 (IL-12 tethered TIL) IND submitted to FDA, with enrollment expected in 2H 2026 across colorectal, breast, and other solid tumors.
8
UK MAA was withdrawn for procedural reasons.
Iovance withdrew its initial UK Marketing Authorization Application in May 2026 (procedural, not safety/efficacy) and will resubmit shortly — an expected delay, but a delay nonetheless.